Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimura, Taku, Sato, Yota, Tanita, Kayo, Kambayashi, Yumi, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Funakoshi, Takeru, Hata, Hiroo, Yamamoto, Yuki, Uchi, Hiroshi, Nonomura, Yumi, Tanaka, Ryota, Aoki, Megumi, Imafuku, Keisuke, Okuhira, Hisako, Furudate, Sadanori, Hidaka, Takanori, Aiba, Setsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884646/
https://www.ncbi.nlm.nih.gov/pubmed/29643991
http://dx.doi.org/10.18632/oncotarget.24509

Ejemplares similares

Ejemplares similares